SUTRO BIOPHARMA, INC. (STRO) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-145.17M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.80× | Operating cash flow / net income. Period ending 2026-06-30. $-145.17M ÷ $-180.55M ≈ 0.80× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -145.17M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 45.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -180.55M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-145.17M | (m) | (m) | $45.70M | (m) | $-180.55M | (m) | (m) | (m) | 0.80× |
| 2026-03-31 | (m) | (m) | $-151.61M | (m) | (m) | $99.61M | (m) | $-153.52M | (m) | (m) | (m) | 0.99× |
| 2025-12-31 | (m) | (m) | $-177.23M | (m) | (m) | $102.48M | (m) | $-191.09M | (m) | (m) | (m) | 0.93× |
| 2025-09-30 | (m) | (m) | $-222.53M | (m) | (m) | $105.65M | (m) | $-216.77M | (m) | (m) | (m) | 1.03× |
| 2025-06-30 | (m) | (m) | $-248.86M | (m) | (m) | $104.47M | (m) | $-208.70M | (m) | (m) | (m) | 1.19× |
| 2025-03-31 | (m) | (m) | $-194.68M | (m) | (m) | $66.43M | (m) | $-245.22M | (m) | (m) | (m) | 0.79× |
| 2024-12-31 | (m) | (m) | $-191.54M | (m) | (m) | $62.04M | (m) | $-227.46M | (m) | (m) | (m) | 0.84× |
| 2024-09-30 | (m) | (m) | $-105.73M | (m) | (m) | $160.96M | (m) | $-123.95M | (m) | (m) | (m) | 0.85× |
| 2024-06-30 | (m) | (m) | $-74.72M | (m) | (m) | $169.36M | (m) | $-124.45M | (m) | (m) | (m) | 0.60× |
| 2024-03-31 | (m) | (m) | $-115.37M | (m) | (m) | $154.06M | (m) | $-114.96M | (m) | (m) | (m) | 1.00× |
| 2023-12-31 | (m) | (m) | $-111.62M | (m) | (m) | $153.73M | (m) | $-106.79M | (m) | (m) | (m) | 1.05× |
| 2023-09-30 | (m) | (m) | $-149.55M | (m) | (m) | $48.64M | (m) | $-172.45M | (m) | (m) | (m) | 0.87× |
| 2023-06-30 | (m) | (m) | $-50.20M | (m) | (m) | $56.87M | (m) | $-142.66M | (m) | (m) | (m) | 0.35× |
| 2023-03-31 | (m) | (m) | $-22.19M | (m) | (m) | $74.55M | (m) | $-130.14M | (m) | (m) | (m) | 0.17× |
| 2022-12-31 | (m) | (m) | $3.55M | (m) | (m) | $67.77M | (m) | $-119.20M | (m) | (m) | (m) | -0.03× |
| 2022-09-30 | (m) | (m) | $5.83M | (m) | (m) | $69.79M | (m) | $-122.73M | (m) | (m) | (m) | -0.05× |
| 2022-06-30 | (m) | (m) | $-84.43M | (m) | (m) | $53.16M | (m) | $-134.15M | (m) | (m) | (m) | 0.63× |
| 2022-03-31 | (m) | (m) | $-86.50M | (m) | (m) | $53.12M | (m) | $-114.29M | (m) | (m) | (m) | 0.76× |
| 2021-12-31 | (m) | (m) | $-81.68M | (m) | (m) | $61.88M | (m) | $-105.54M | (m) | (m) | (m) | 0.77× |
| 2021-09-30 | (m) | (m) | $-78.98M | (m) | (m) | $59.50M | (m) | $-126.96M | (m) | (m) | (m) | 0.62× |
| 2021-06-30 | (m) | (m) | $-72.26M | (m) | (m) | $68.81M | (m) | $-78.92M | (m) | (m) | (m) | 0.92× |
| 2021-03-31 | (m) | (m) | $-79.50M | (m) | (m) | $50.23M | (m) | $-42.89M | (m) | (m) | (m) | 1.85× |
| 2020-12-31 | (m) | (m) | $-67.80M | (m) | (m) | $42.72M | (m) | $-32.13M | (m) | (m) | (m) | 2.11× |
| 2020-09-30 | (m) | (m) | $-62.08M | (m) | (m) | $45.75M | (m) | $12.63M | (m) | (m) | (m) | -4.92× |
| 2020-06-30 | (m) | (m) | $-60.51M | (m) | (m) | $40.20M | (m) | $-17.42M | (m) | (m) | (m) | 3.47× |
| 2020-03-31 | (m) | (m) | $-63.61M | (m) | (m) | $41.26M | (m) | $-61.09M | (m) | (m) | (m) | 1.04× |
| 2019-12-31 | (m) | (m) | $-65.02M | (m) | (m) | $42.74M | (m) | $-55.74M | (m) | (m) | (m) | 1.17× |
| 2019-09-30 | $-60.03M | (m) | $-57.80M | $2.23M | (m) | $50.52M | (m) | $-42.45M | (m) | (m) | -118.84% | 1.36× |
| 2019-06-30 | $3.97M | (m) | $5.89M | $1.92M | (m) | $46.08M | (m) | $-39.77M | (m) | (m) | 8.62% | -0.15× |
| 2019-03-31 | $6.08M | (m) | $7.55M | $1.47M | (m) | $41.26M | (m) | $-37.52M | (m) | (m) | 14.74% | -0.20× |
| 2018-12-31 | $11.13M | (m) | $12.68M | $1.56M | (m) | $38.42M | (m) | $-35.32M | (m) | (m) | 28.96% | -0.36× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $33.04M | (m) | $-40.35M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $42.69M | (m) | $-30.62M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-40.39M | (m) | $-37.07M | $3.32M | (m) | $51.74M | (m) | $-19.69M | (m) | (m) | -78.06% | 1.88× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-17.55M | (m) | $-13.15M | $4.39M | (m) | $59.73M | (m) | $1.70M | (m) | (m) | -29.38% | -7.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |